Physician profile
Ryan Beatty
NPI 1427710227
$1,949.95
in general payments reported to CMS, 2019-2025
17 companies · $631 in 2025
The $631 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.19 · 2022: $594 · 2023: $631 · 2024: $77.76 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,339.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $550.98 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $289.25 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $218.63 | 2022-2023 | Rexulti |
| Corium, LLC | $175.79 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $148.25 | 2022-2023 | Qelbree |
| Alkermes, INC. | $108.23 | 2023-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $86.54 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $84.54 | 2022-2025 | Spravato |
| Tris Pharma INC | $70.64 | 2023-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $57.94 | 2022-2023 | Austedo, Austedo Xr |
| Axsome Therapeutics, INC. | $46.61 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $28.14 | 2022-2023 | Trintellix |
| Neos Therapeutics, LP | $19.53 | 2023 | Adzenys Xr-Odt |
| Vertical Pharmaceuticals, LLC | $18.32 | 2025 | Relexxii |
| E.R. Squibb & Sons, L.L.C. | $17.00 | 2025 | Cobenfy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $16.70 | 2025 | |
| Noven Therapeutics, LLC | $12.86 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Beatty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.